296 related articles for article (PubMed ID: 24117602)
1. Prediction of liver stiffness hepatocellular carcinoma in chronic hepatitis C patients on interferon-based anti-viral therapy.
Narita Y; Genda T; Tsuzura H; Sato S; Kanemitsu Y; Ishikawa S; Kikuchi T; Hirano K; Iijima K; Wada R; Ichida T
J Gastroenterol Hepatol; 2014 Jan; 29(1):137-43. PubMed ID: 24117602
[TBL] [Abstract][Full Text] [Related]
2. Liver stiffness-based score in hepatoma risk assessment for chronic hepatitis C patients after successful antiviral therapy.
Wang JH; Yen YH; Yao CC; Hung CH; Chen CH; Hu TH; Lee CM; Lu SN
Liver Int; 2016 Dec; 36(12):1793-1799. PubMed ID: 27254286
[TBL] [Abstract][Full Text] [Related]
3. Liver stiffness measurement as an alternative to fibrotic stage in risk assessment of hepatocellular carcinoma incidence for chronic hepatitis C patients.
Wang HM; Hung CH; Lu SN; Chen CH; Lee CM; Hu TH; Wang JH
Liver Int; 2013 May; 33(5):756-61. PubMed ID: 23405889
[TBL] [Abstract][Full Text] [Related]
4. The tertiary prevention of hepatocellular carcinoma in chronic hepatitis C patients.
Huang JF; Yeh ML; Yu ML; Dai CY; Huang CF; Huang CI; Tsai PC; Lin PC; Chen YL; Chang WT; Hou NJ; Lin ZY; Chen SC; Chuang WL
J Gastroenterol Hepatol; 2015 Dec; 30(12):1768-74. PubMed ID: 26094738
[TBL] [Abstract][Full Text] [Related]
5. Impact of liver-stiffness measurement on hepatocellular carcinoma development in chronic hepatitis C patients treated with direct-acting antivirals: A systematic review and time-to-event meta-analysis.
You MW; Kim KW; Shim JJ; Pyo J
J Gastroenterol Hepatol; 2021 Mar; 36(3):601-608. PubMed ID: 32875681
[TBL] [Abstract][Full Text] [Related]
6. Sustained virological response to pegylated interferon plus ribavirin leads to normalization of liver stiffness in hepatitis C virus-infected patients.
Macías J; Rivero A; Cifuentes C; Camacho A; Neukam K; Rivero-Juárez A; Mira JA; Torre-Cisneros J; Gómez-Mateos J; Pineda JA
Enferm Infecc Microbiol Clin; 2013; 31(7):424-9. PubMed ID: 23453582
[TBL] [Abstract][Full Text] [Related]
7. Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients.
Hung CH; Lu SN; Wang JH; Hu TH; Chen CH; Huang CM; Lee CM
Antivir Ther; 2011; 16(7):959-68. PubMed ID: 22024511
[TBL] [Abstract][Full Text] [Related]
8. Effect of peginterferon alfa-2b and ribavirin on hepatocellular carcinoma prevention in older patients with chronic hepatitis C.
Honda T; Ishigami M; Masuda H; Ishizu Y; Kuzuya T; Hayashi K; Itoh A; Hirooka Y; Nakano I; Ishikawa T; Urano F; Yoshioka K; Toyoda H; Kumada T; Katano Y; Goto H
J Gastroenterol Hepatol; 2015 Feb; 30(2):321-8. PubMed ID: 25091027
[TBL] [Abstract][Full Text] [Related]
9. Risk factors of hepatocellular carcinoma development in non-cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection.
Toyoda H; Kumada T; Tada T; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Kitabatake S; Ito T
J Gastroenterol Hepatol; 2015 Jul; 30(7):1183-9. PubMed ID: 25678094
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of pegylated interferon and ribavirin combination therapy for patients with hepatitis C virus infection after curative resection or ablation for hepatocellular carcinoma--A retrospective multicenter study.
Harada N; Hiramatsu N; Oze T; Tatsumi T; Hayashi N; Takehara T
J Med Virol; 2015 Jul; 87(7):1199-206. PubMed ID: 25772024
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: a prospective, multicenter study.
Ogawa E; Furusyo N; Kajiwara E; Takahashi K; Nomura H; Maruyama T; Tanabe Y; Satoh T; Nakamuta M; Kotoh K; Azuma K; Dohmen K; Shimoda S; Hayashi J;
J Hepatol; 2013 Mar; 58(3):495-501. PubMed ID: 23099187
[TBL] [Abstract][Full Text] [Related]
12. The incidence and risk factors for the development of hepatocellular carcinoma after peginterferon plus ribavirin therapy for chronic hepatitis C.
Dohmen K; Kawano A; Takahashi K; Shigematsu H; Tanaka H; Haruno M; Yanagita K; Ichiki Y; Mori T; Hayashida K; Shimoda S; Ishibashi H; Nomura H
Hepatogastroenterology; 2013; 60(128):2034-8. PubMed ID: 24719946
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety of pegylated interferon plus ribavirin combination therapy in chronic hepatitis c patients with hepatocellular carcinoma post curative therapies - a multicenter prospective trial.
Huang JF; Yu ML; Huang CF; Chiu CF; Dai CY; Huang CI; Yeh ML; Yang JF; Hsieh MY; Hou NJ; Lin ZY; Chen SC; Wang LY; Chuang WL
J Hepatol; 2011 Feb; 54(2):219-26. PubMed ID: 21056500
[TBL] [Abstract][Full Text] [Related]
14. Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients.
Tanaka H; Tsukuma H; Kasahara A; Hayashi N; Yoshihara H; Masuzawa M; Kanda T; Kashiwagi T; Inoue A; Kato M; Oshima A; Kinoshita Y; Kamada T
Int J Cancer; 2000 Sep; 87(5):741-9. PubMed ID: 10925370
[TBL] [Abstract][Full Text] [Related]
15. α-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C.
Asahina Y; Tsuchiya K; Nishimura T; Muraoka M; Suzuki Y; Tamaki N; Yasui Y; Hosokawa T; Ueda K; Nakanishi H; Itakura J; Takahashi Y; Kurosaki M; Enomoto N; Nakagawa M; Kakinuma S; Watanabe M; Izumi N
Hepatology; 2013 Oct; 58(4):1253-62. PubMed ID: 23564522
[TBL] [Abstract][Full Text] [Related]
16. Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon-based antiviral therapy.
Hung CH; Lee CM; Wang JH; Hu TH; Chen CH; Lin CY; Lu SN
Int J Cancer; 2011 May; 128(10):2344-52. PubMed ID: 20669224
[TBL] [Abstract][Full Text] [Related]
17. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
18. Higher risk of hepatocellular carcinoma in chronic hepatitis B vs chronic hepatitis C after achievement of virologic response.
Kim GA; Han S; Kim HD; An J; Lim YS
J Viral Hepat; 2017 Nov; 24(11):990-997. PubMed ID: 28499070
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C.
Arase Y; Ikeda K; Suzuki F; Suzuki Y; Saitoh S; Kobayashi M; Akuta N; Someya T; Koyama R; Hosaka T; Sezaki H; Kobayashi M; Kumada H
Intervirology; 2007; 50(1):16-23. PubMed ID: 17164553
[TBL] [Abstract][Full Text] [Related]
20. Prediction of hepatocellular carcinoma using age and liver stiffness on transient elastography after hepatitis C virus eradication.
Nakai M; Yamamoto Y; Baba M; Suda G; Kubo A; Tokuchi Y; Kitagataya T; Yamada R; Shigesawa T; Suzuki K; Nakamura A; Sho T; Morikawa K; Ogawa K; Furuya K; Sakamoto N
Sci Rep; 2022 Jan; 12(1):1449. PubMed ID: 35087141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
